Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an Experts Panel Meeting

C. Gridelli, P. Maione, D. Amoroso, M. Baldari, A. Bearz, V. Bettoli, E. Cammilluzzi, L. Crinò, F. De Marinis, F. A. Di Pietro, F. Grossi, D. Innocenzi, G. Micali, F. V. Piantedosi, M. Scartozzi

Research output: Contribution to journalArticle

Abstract

Advances in the knowledge of tumor biology and mechanisms of oncogenesis has granted the singling out of several molecular targets for non-small cell lung cancer (NSCLC) treatment. Among these targets, epidermal growth factor receptor (EGFR), or HER1, has received particular attention in lung cancer treatment. Erlotinib, an orally available inhibitor of EGFR tyrosine kinase in a phase III randomized placebo-controlled trial (BR.21), has been proven to prolong survival in NSCLC patients after first or second line chemotherapy. Skin rash is the most common adverse event associated with erlotinib treatment and it is often cause of negative impact on patients' quality of life. There is no specific treatment for this toxicity due to the lack of evidence-based data and recommendations. A panel of Italian oncologists, who had participated to clinical trials and to the Expanded Access Program for erlotinib in NSCLC treatment, and dermatologists with experience with cutaneous toxicity from EGFR inhibitors, attended a Meeting held in Rome on December 2006 to discuss skin rash from erlotinib and to provide suggestions for managing this frequent side-effect.

Original languageEnglish
Pages (from-to)155-162
Number of pages8
JournalCritical Reviews in Oncology/Hematology
Volume66
Issue number2
DOIs
Publication statusPublished - May 2008

Fingerprint

Exanthema
Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Therapeutics
Protein-Tyrosine Kinases
Lung Neoplasms
Carcinogenesis
Randomized Controlled Trials
Placebos
Quality of Life
Erlotinib Hydrochloride
Clinical Trials
Drug Therapy
Skin
Survival
Neoplasms

Keywords

  • EGFR
  • EGFR inhibitors
  • Erlotinib
  • NSCLC
  • Skin rash

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients : Results of an Experts Panel Meeting. / Gridelli, C.; Maione, P.; Amoroso, D.; Baldari, M.; Bearz, A.; Bettoli, V.; Cammilluzzi, E.; Crinò, L.; De Marinis, F.; Di Pietro, F. A.; Grossi, F.; Innocenzi, D.; Micali, G.; Piantedosi, F. V.; Scartozzi, M.

In: Critical Reviews in Oncology/Hematology, Vol. 66, No. 2, 05.2008, p. 155-162.

Research output: Contribution to journalArticle

Gridelli, C, Maione, P, Amoroso, D, Baldari, M, Bearz, A, Bettoli, V, Cammilluzzi, E, Crinò, L, De Marinis, F, Di Pietro, FA, Grossi, F, Innocenzi, D, Micali, G, Piantedosi, FV & Scartozzi, M 2008, 'Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an Experts Panel Meeting', Critical Reviews in Oncology/Hematology, vol. 66, no. 2, pp. 155-162. https://doi.org/10.1016/j.critrevonc.2007.10.004
Gridelli, C. ; Maione, P. ; Amoroso, D. ; Baldari, M. ; Bearz, A. ; Bettoli, V. ; Cammilluzzi, E. ; Crinò, L. ; De Marinis, F. ; Di Pietro, F. A. ; Grossi, F. ; Innocenzi, D. ; Micali, G. ; Piantedosi, F. V. ; Scartozzi, M. / Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients : Results of an Experts Panel Meeting. In: Critical Reviews in Oncology/Hematology. 2008 ; Vol. 66, No. 2. pp. 155-162.
@article{851bf490159c4265914dc8e44589c13a,
title = "Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an Experts Panel Meeting",
abstract = "Advances in the knowledge of tumor biology and mechanisms of oncogenesis has granted the singling out of several molecular targets for non-small cell lung cancer (NSCLC) treatment. Among these targets, epidermal growth factor receptor (EGFR), or HER1, has received particular attention in lung cancer treatment. Erlotinib, an orally available inhibitor of EGFR tyrosine kinase in a phase III randomized placebo-controlled trial (BR.21), has been proven to prolong survival in NSCLC patients after first or second line chemotherapy. Skin rash is the most common adverse event associated with erlotinib treatment and it is often cause of negative impact on patients' quality of life. There is no specific treatment for this toxicity due to the lack of evidence-based data and recommendations. A panel of Italian oncologists, who had participated to clinical trials and to the Expanded Access Program for erlotinib in NSCLC treatment, and dermatologists with experience with cutaneous toxicity from EGFR inhibitors, attended a Meeting held in Rome on December 2006 to discuss skin rash from erlotinib and to provide suggestions for managing this frequent side-effect.",
keywords = "EGFR, EGFR inhibitors, Erlotinib, NSCLC, Skin rash",
author = "C. Gridelli and P. Maione and D. Amoroso and M. Baldari and A. Bearz and V. Bettoli and E. Cammilluzzi and L. Crin{\`o} and {De Marinis}, F. and {Di Pietro}, {F. A.} and F. Grossi and D. Innocenzi and G. Micali and Piantedosi, {F. V.} and M. Scartozzi",
year = "2008",
month = "5",
doi = "10.1016/j.critrevonc.2007.10.004",
language = "English",
volume = "66",
pages = "155--162",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients

T2 - Results of an Experts Panel Meeting

AU - Gridelli, C.

AU - Maione, P.

AU - Amoroso, D.

AU - Baldari, M.

AU - Bearz, A.

AU - Bettoli, V.

AU - Cammilluzzi, E.

AU - Crinò, L.

AU - De Marinis, F.

AU - Di Pietro, F. A.

AU - Grossi, F.

AU - Innocenzi, D.

AU - Micali, G.

AU - Piantedosi, F. V.

AU - Scartozzi, M.

PY - 2008/5

Y1 - 2008/5

N2 - Advances in the knowledge of tumor biology and mechanisms of oncogenesis has granted the singling out of several molecular targets for non-small cell lung cancer (NSCLC) treatment. Among these targets, epidermal growth factor receptor (EGFR), or HER1, has received particular attention in lung cancer treatment. Erlotinib, an orally available inhibitor of EGFR tyrosine kinase in a phase III randomized placebo-controlled trial (BR.21), has been proven to prolong survival in NSCLC patients after first or second line chemotherapy. Skin rash is the most common adverse event associated with erlotinib treatment and it is often cause of negative impact on patients' quality of life. There is no specific treatment for this toxicity due to the lack of evidence-based data and recommendations. A panel of Italian oncologists, who had participated to clinical trials and to the Expanded Access Program for erlotinib in NSCLC treatment, and dermatologists with experience with cutaneous toxicity from EGFR inhibitors, attended a Meeting held in Rome on December 2006 to discuss skin rash from erlotinib and to provide suggestions for managing this frequent side-effect.

AB - Advances in the knowledge of tumor biology and mechanisms of oncogenesis has granted the singling out of several molecular targets for non-small cell lung cancer (NSCLC) treatment. Among these targets, epidermal growth factor receptor (EGFR), or HER1, has received particular attention in lung cancer treatment. Erlotinib, an orally available inhibitor of EGFR tyrosine kinase in a phase III randomized placebo-controlled trial (BR.21), has been proven to prolong survival in NSCLC patients after first or second line chemotherapy. Skin rash is the most common adverse event associated with erlotinib treatment and it is often cause of negative impact on patients' quality of life. There is no specific treatment for this toxicity due to the lack of evidence-based data and recommendations. A panel of Italian oncologists, who had participated to clinical trials and to the Expanded Access Program for erlotinib in NSCLC treatment, and dermatologists with experience with cutaneous toxicity from EGFR inhibitors, attended a Meeting held in Rome on December 2006 to discuss skin rash from erlotinib and to provide suggestions for managing this frequent side-effect.

KW - EGFR

KW - EGFR inhibitors

KW - Erlotinib

KW - NSCLC

KW - Skin rash

UR - http://www.scopus.com/inward/record.url?scp=41449095523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41449095523&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2007.10.004

DO - 10.1016/j.critrevonc.2007.10.004

M3 - Article

C2 - 18083041

AN - SCOPUS:41449095523

VL - 66

SP - 155

EP - 162

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -